IMRAN NAZEER
*** ******** ****., ******, ** *****
(Cell) 936-***-****, E-Mail: ****.******@*****.***
With more than 26 years of clinical, administrative and teaching experience, looking for an opportunity to continue that passion.
EDUCATION
1994, 2009 & 2019 A.B.I.M. ( Internal Medicine) Recertified
November 1996,2009, 2019 A.B.I.M. (Nephrology) ReCertified
November 1991 M.R.C.P. (UK), Royal College of Physicians, London, UK September 1985 M.B.B.S., King Edward Medical College, Punjab University,
Lahore, Pakistan
POST DOCTORAL EDUCATION
July 1995 to Research Fellow, Renal Medicine
June 1996 VA Medical Center, Minneapolis, MN 55417
July 1994 to Clinical Fellow, Renal Medicine
June 1995 University of Minnesota, Minneapolis, MN 55455
July 1992 to Resident (PGY 2,3) Internal Medicine, St Mary’s Hospital,
June 1994 University of Rochester, School of Medicine, Rochester, NY 14611
August 1990 to Senior House Officer (equiv. to PGY 4,5,6), Internal Medicine,
June 1992 Russells Hall Hospital, Dudley Health Authority, W. Midlands, England (Affiliate of University of Birmingham, School of Medicine, England)
September 1985 to Senior House Officer/ Registrar (equiv. PGY 1,2,3,4) Internal Medicine, Mayo
December 1989 Hospital, Lahore, Pakistan (Affiliate of King Edward Medical University)
CLINICAL and ADMINISTRATION EXPERIENCE
Interventional Nephrology Training (2001), Capitol Nephrology Group, Austin, Texas (Dialysis access thrombolysis, venograms, angioplasty, permcath placements)
Ultrasound in Nephrology training (2000), Emory University, Atlanta, GA. Dr Charles O’Neil
Nephrology Practice (1996 to-date), East Texas Nephrology Associates, Lufkin, Texas.
President, East Texas Nephrology Associates. Responsible for administrative work for 9 employees for smooth and profitable running of the office. Managing a Provider staff of 3 Nephrologists and 3 mid level Nurse Practitioners.
Inpatient service in 2 local hospitals (Woodland Heights medical center- 120 beds and CHI-St Luke’s Medical Center of East Texas Affiliated with Baylor COllege of Medicine- 250 beds; Average daily hospital census 25-35 patients for our group)
Office Practice with weekly average 40 patients per Provider follow up and 8-15 new office consults per week
Associate Medical Director (1996-2006) and then Medical director, In- Center Dialysis facilities in Lufkin and Livingston, TX (2006- to-date) (approx. 200 patients) responsible for overseeing compliance with local, state and federal regulating agencies, safety and quality care of patients. Conducting monthly rounds, QA and Governing Body meetings
Acute Dialysis Medical Director (2022 to-date) for CHI St Luke’s Medical Center, Lufkin TX
Office Based Interventional Nephrologist @ E T Nephrology Associates (2016-2020)
Nephrology Service Line with CHI- St Luke’s Medical Center of East Texas, Lufkin (2018 to-date) with Quality improvement projects, Service Line Development, enhancing Home Therapies, Teaching and educating the nursing staff, enhancing and streamlining Patient Education, and lowering Sepsis Mortality.
Home Therapy Program at i-Dialysis, Nacogdoches to enhance Peritoneal dialysis and Home Hemodialysis. (2018 to-date)
Renal Transplant Workup program initiated with collaboration of CHI Baylor- St Luke’s Medical Center, Houston and CHI- St Luke’s Medical Center of East Texas, Lufkin (2020 to date) to do initial transplant evaluation of patients in Lufkin, to improve access to care. .
Clinical Research with P and I Clinical Research since 2017 to date. Have done short of 6-8 studies so far.
Teaching of PA Students from UTMB, Galveston, TX, Medical Students from Sam Houston State University, and New Nurses at CHI- St Luke’s Medical Center of East Texas, Lufkin
Conflict Management Course (Coursera 2021)
The Fuqua School of Business, Duke University, Durham, North Carolina week long course in association with RPA (2011)
Telemedicine experience (2020 to date) Proficient in Video calling on different platforms (TEAMS, Zoom, Google Duo, FaceTime, Doximity).
LICENSURE/CERTIFICATE
August 1996 Texas Board of Medical Examiners # K 0954
January 1995 DEA Certificate # BN 4301204
September 1994 Minnesota Board of Medical Practice # 37472
January 1990 General Medical Council, UK (British License)
SOCIETY MEMBERSHIPS
Texas Medical Association / Angelina Medical Society
Renal Physician Association
Past Memberships: MGMA, AAPE (American Association of Physician Executives)
COMMITTEE MEMBERSHIPS
2018- to-date Board Member, WHMC, Lufkin, TX (working with members to improve quality of services, maintain culture of safety, patient experience, developing services, maintain budget and strategic discussions).
2010-2011 Chief of Medicine, Woodland Heights Medical Center, Lufkin, TX
2008-2011 Chairman, Pharmacy and Therapeutics Committee, CHI- St Luke’s Medical Center of East Texas, Lufkin
2001- 2002 Chairman, Pharmacy and Therapeutics Committee, CHI- St Luke’s Medical Center of East Texas, Lufkin
1996-2001 Member, Pharmacy and Therapeutics Committee, CHI- St Luke’s Medical Center of East Texas, Lufkin
CLINICAL RESEARCH
Principal Investigator (since 2011)
Randomized, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetic and non- diabetic chronic kidney disease (2022)
A Randomized, Double-Masked, Placebo-Controlled, Multicenter,
Phase 2 Study to Evaluate the Safety and Renal Efficacy ofLY2382770 in Patients with Diabetic Kidney Disease Due to Type 1 or Type 2 Diabetes
Therapeutic-Equivalence Study Comparing the Efficacy and Safety of Subcutaneous Epoetin Hospira and Epoetin Alfa in Patients with Chronic Renal Failure, Phase I
Long-Term Safety Study of Subcutaneous Epoetin
Hospira in Patients with Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance, Phase III
A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes, Phase IV
Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection with Pyelonephritis
Phase 3, Multicenter,Randomized, Double-Blind, Placebo-Controlled, Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
Potassium and Cardiac Rhythm Trends in Maintenance Hemodialysis (POTEND): A Multicenter, Prospective, Observational Study
Others:
Role of Nitric Oxide System in Cyclosporine –Induced Hypertension—animal and human studies. 1995.
Cryptic Vancomycin –Resistant Staphylococci (CV-RS) as a cause of treatment failure in staphylococcus aureus (S.a.) Bacteremia. Abstract submitted to 35th ICAAC, American Society of Microbiology. 1995
Anterior Pituitary Tumors presenting with Diabetes Insipidus: Review of the world literature. 1995
Ehrlichiosis causing acute renal failure and disseminated intravascular coagulation- case report poster presentation at ACP clinical vignette competition Minnesota chapter, University of Minnesota, Minneapolis, MN
Pregnancy Induced Hypertension –a review. St Mary’s Hospital, Rochester, NY, USA.1994
Case Report: Paraesophageal hernia causing gastric outlet obstruction. St Mary’s hospital, Rochester, NY, USA. 1993
Compilation of current literature regarding CELIPROLOL for use by the Department of Medicine, Russells Hall Hospital, Dudley, England. 1991
Active participation in the clinical trials of ISIS 3 and ISIS 4 conducted at Russells Hall Hospital, Dudley, England. 1991
Retrospective analysis of morbidity and mortality in Tetanus. Mayo Hospital, Lahore, Pakistan. 1988
Design of a prospective study of Role of Mannitol in Hepatic Coma, Mayo Hospital, Lahore, Pakistan. 1987
Statistical analysis of a study of Role of Sylimarin in Hepatitis A. Mayo Hospital, Lahore, Pakistan. 1986.
Renal Transplant Project (first ever), Mayo Hospital, Lahore, Pakistan. 1985